Funding
This work was supported by the Australian Research Council (ARC;
CE140100011), the National Health and Medical Research Council,
Australia (NHMRC 1113293), AIFA research grant (CFA and JAT, 2021);
NHMRC investigator grant (JAT, 1139902). DIG was supported by an NHMRC
Senior Principal Research Fellowship (1117766). DIG has also served as a
paid member of an advisory committee, and shareholder, for Avalia
Immunotherapies.